CMI Dr. Busegeanu Mihaela Magdalena
- Address
- Strada Alexandru Odobescu, Nr. 30, Prahova, 100342 Ploieşti, Romania
CMI Dr. Busegeanu Mihaela Magdalena - Lipid Metabolism Research
CMI Dr. Busegeanu Mihaela Magdalena is a clinical research facility dedicated to advancing the understanding and treatment of metabolic disorders, with particular emphasis on lipid abnormalities. The center specializes in conducting clinical trials that evaluate novel therapeutic interventions for patients with significant cardiovascular risk factors related to lipid metabolism.
- Severe hypertriglyceridemia (SHTG) treatment studies
- Advanced lipid-lowering therapies including RNA-based interventions
- Cardiovascular risk reduction in high-risk metabolic populations
The center demonstrates expertise in evaluating cutting-edge pharmacological approaches, particularly focusing on fasting serum triglyceride reduction in patients with severe hypertriglyceridemia. Through participation in international multicenter trials, CMI Dr. Busegeanu contributes to the development of innovative therapies that address unmet needs in lipid disorder management and cardiovascular disease prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CMI Dr. Busegeanu Mihaela Magdalena
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals Inc. | Phase III | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 1 | Unknown | 2023-11-07 | 2023-11-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.